DCM
RLAY icon

Dupont Capital Management’s Relay Therapeutics RLAY Stock Holding History

Dupont Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,396
Closed -$124K – 1660
2022
Q2 		$124K Hold
7,396
– – 0.01% 1139
2022
Q1 		$221K Buy
7,396
+2,190
+42% +$53.1K 0.01% 1030
2021
Q4 		$160K Sell
5,206
-2,076
-29% -$65.6K 0.01% 1193
2021
Q3 		$230K Buy
+7,282
New +$245K 0.01% 1190

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Dupont Capital Management's RLAY Position: Q3 2022 in Review

Dupont Capital Management sold out of Relay Therapeutics (RLAY) in Q3 2022, closing a stake of 7,396 shares — an estimated $124K sold.

Dupont Capital Management first reported a position in RLAY in Q3 2021 and held it in 4 quarters. The position peaked at $230K in Q3 2021. 161 funds tracked by Wall St. Rank hold RLAY as of Q3 2022.

  • Dupont Capital Management reported no remaining Relay Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Dupont Capital Management sold 7,396 Relay Therapeutics shares in Q3 2022, an estimated $124K.
  • Dupont Capital Management first reported a position in Relay Therapeutics in Q3 2021 and held it in 4 quarters.
  • Dupont Capital Management's Relay Therapeutics position peaked at $230K in Q3 2021.
  • 161 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.